Check Claims Before You Publish

Core evidence (representative, high-quality items)

• Landmark randomized phase 3 trial of nivolumab ± ipilimumab showing clinically meaningful benefits in untreated advanced melanoma (practice-changing; high citation impact):
  NEJM 2015 Nivo+Ipi
• Long-term overall survival data supporting combined checkpoint inhibition durability:
  NEJM 2017 OS follow-up
• Broad synthesis on immune-related adverse events (irAEs) — clinical guidance and mechanism summary:
  NEJM irAE review 2018
• Translational/biomarker work linking genomic features to checkpoint response (illustrates Postow's involvement in mechanistic/translational studies):
  NEJM 2014 genetic basis CTLA-4
• Clinical commentary on targeted therapy in NRAS-mutant melanoma (Lancet Oncology):
  Lancet Oncol commentary on NEMO

Synthesis — strengths, limitations, blindspots

• Strengths: sustained presence as co-author on multiple high-impact, practice-changing randomized trials and translational studies (NEJM RCTs, biomarker papers), and a widely-used clinical review on irAEs — this combination shows both trial leadership and synthesis roles that shape practice and research priorities NEJM 2015.
• Limitations / blindspots: (1) many high-profile works are multi-author, large-consortium trials — contribution magnitude varies and single-author intellectual fingerprint is less isolated; (2) COI disclosures are present in commentary pieces (industry fees/grants) which should be considered when interpreting opinion pieces (Lancet Oncology commentary lists MAP fees/grants) Lancet Oncol COI;
• Evidence balance: Postow's highest-impact outputs are empirical RCTs and translational analyses published in top-tier journals — that is high-quality evidence; however, for narrower or lower-volume topics in his smaller-author dataset (e.g., survivorship/long-term irAE surveillance), empirical long-term data remain limited and Postow has called for more long-term follow-up (explicit in survivorship commentary), indicating responsible identification of knowledge gaps.
• Potential biases to watch: publication bias (positive trials favored), consortium authorship diluting attribution, and COI/institutional relationships when interpreting opinion/commentary pieces; these are normal in clinical oncology but should be reported and weighed.

What would change this assessment?

1. Evidence lowering Postow's scientific weight: independent, high-quality replications showing that the clinical benefits reported were overstated or safety profiles worse than reported would reduce impact — but current RCT and long-term follow-up data are robust.
2. Evidence increasing Postow's standing: additional first-author mechanistic papers that establish causal mechanisms linking observed clinical outcomes to novel biology, or leadership of further independent randomized trials where he is first/last author would further strengthen single-author intellectual attribution.

Selected citations (representative, high-evidence items)